Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

Slides:

Advertisements

Similar presentations

Kendrick Sparks, PGY3 September 17, 2015

Advertisements

Are the PCSK9 Inhibitors the Panacea of Atherosclerosis Treatment?

Update on the Role of PCSK9 in the Treatment of the High-Risk CVD

Statin Myopathy (AHA/ACC/NHLBI)

for patients with dyslipidemia & previous stroke/TIA

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

PCSK9 Inhibitors and Cardiovascular Outcomes Trials

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

PCSK9 Inhibitors Post-CVOTs

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Cholesteryl Ester Transfer Protein Inhibitors

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

American Heart Association Scientific Sessions

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Beyond Statin Therapy.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

An Update on PCSK9 Inhibitors

A Pharmacist's Guide to PCSK9 Inhibitors:

Evaluating LDL-C Recommendations

New Pathways in Lipid Care

What's New in Dyslipidemia?

62-year-old Man With Unstable Angina

PCSK9 Inhibitors and Cardiovascular Outcomes

% decrease in LDL-C at 24 weeks from baseline

% decrease in LDL-C at 24 weeks from baseline

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

A Patient Journey Through Statin Intolerance

Improving Appropriate Access to PCSK9 Inhibitors

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche, PhD,

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

New LDL-C Lipid Targets

A PCP's Guide to Dyslipidemia

Radical New Concepts in Lipid Management

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

Clinicians' Corner in Dyslipidemia

Updates in Cardiovascular Medicine

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Monoclonal Antibodies in CVD: What Does the Future Hold?

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

PCSK9 Mutations PCSK9 Loss-of-function Mutations.

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Latest Lipid Guidelines in Perspective

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Reducing Risk for CV Outcomes

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

A Family Affair.

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Achieving Lipid Targets With PCSK9 Inhibition

Lipids, the Heart, and the Kidney

Putting Your Skills to the Test

PCSK9 Inhibitors and Real-World Evidence

Shared-Decision Making in Dyslipidemia

Presentation transcript:

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

ARIC PCSK9 Loss-of-Function Mutations, LDL-C, and CHD Risk

PCSK9-Directed Therapies in Development

Effects of Evolocumab (AMG-145) on LDL-C Levels Phase 1b Study Design

Evolocumab -- Phase 1b Change in LDL-C at 2- and 4-Week Dosing Intervals on Statin Therapy

PCSK9 Inhibitors Phase 2

MENDEL Evolocumab Phase 2 Monotherapy in Patients With Hypercholesterolemia

MENDEL Study Design

MENDEL Evolocumab Monotherapy for Hypercholesterolemia

PCSK9 Inhibitors Phase 2

Alirocumab (SAR236553) Add-on to Atorvastatin

Alirocumab Change in LDL-C at 2- and 4-Week Dosing Intervals on Atorvastatin

Alirocumab on Top of Atorvastatin in Primary Hypercholesterolemia

LAPLACE-TIMI 57 Evolocumab in Combination With Statin in Patients With Hypercholesterolemia

LAPLACE-TIMI 57 Study Design

LAPLACE-TIMI 57 Effect of Evolocumab on Percentage Change in LDL-C From Baseline

Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin Therapy Phase 2 Studies

Intravenous RN316 in Hypercholesterolemic Patients on High- or Maximum-Dose Statin Therapy Doses Studied

Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin Therapy Pooled Results

PCSK9 Inhibitors Phase 2

GAUSS Phase 2 Evolocumab in Statin-Intolerant Patients

GAUSS Evolocumab in Statin Intolerance

PCSK9 Inhibitors Phase 2

Effect of Alirocumab on LDL-C in Heterozygous FH

RUTHERFORD Phase 2 Evolocumab in Patients With Heterozygous FH

RUTHERFORD Effect of Evolocumab on LDL-C in Heterozygous FH

Phase 3 Trials

OSLER Phase 3 Extension Study

OSLER Effect of Evolocumab on LDL-C after 52 Weeks

ODYSSEY Outcomes Phase 3 Post-ACS With Alirocumab

References

References (cont)

References (cont)